FOLFIRI + Cetuximab
ApprovedMonoclonal antibody
FOLFIRI + Cetuximab is one of 68 small molecule programs targeting Colorectal Carcinoma. It is currently in Approved.
2
Indications
5
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Vectibix
AmgenPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Erbitux
IImclone
Phase 3
Sutent
PfizerPhase 3
Alinia
RRomark Laboratories L.C.
Phase 3
HX008
BBinhui Biopharmaceutical Co., Ltd.
Phase 3
FOLFIRI + Cetuximab
AArbeitsgemeinschaft medikamentoese Tumortherapie
Approved
Oxaliplatin, /m2
RochePhase 3
Leucovorin /m^2
RochePhase 3
Eylea
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer3 trials
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT01910610·464 enrolled
FOLFIRI in Combination With Cetuximab in the First-line Treatment of Metastatic Colorectal Cancer Including a Regular Dermal Prophylaxis to Prevent Acneiforme Follicular Exanthema
Unknown status·—·Phase 4·NCT01315990·165 enrolled
Colorectal Tumors1 trial
Colorectal Carcinoma1 trial
Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT01640444·240 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FOLFIRI + Cetuximab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details